Duquesne Family Office LLC Takes $629,000 Position in Invivyd, Inc. (NASDAQ:IVVD)

Duquesne Family Office LLC acquired a new position in Invivyd, Inc. (NASDAQ:IVVD) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 571,425 shares of the company’s stock, valued at approximately $629,000. Duquesne Family Office LLC owned approximately 0.48% of Invivyd at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Cubist Systematic Strategies LLC increased its holdings in shares of Invivyd by 66.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after purchasing an additional 53,499 shares during the period. Marshall Wace LLP increased its stake in Invivyd by 4.2% in the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock valued at $866,000 after buying an additional 31,992 shares during the period. XTX Topco Ltd increased its stake in Invivyd by 68.1% in the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock valued at $42,000 after buying an additional 15,376 shares during the period. Renaissance Technologies LLC purchased a new stake in Invivyd in the 2nd quarter worth approximately $421,000. Finally, Cornercap Investment Counsel Inc. acquired a new stake in shares of Invivyd during the 2nd quarter valued at $86,000. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Invivyd Stock Performance

Shares of NASDAQ IVVD opened at $0.98 on Thursday. The business has a 50 day simple moving average of $1.06 and a 200 day simple moving average of $1.87. Invivyd, Inc. has a 52 week low of $0.81 and a 52 week high of $5.20. The stock has a market cap of $116.93 million, a price-to-earnings ratio of -0.52 and a beta of 0.61.

Invivyd (NASDAQ:IVVD) last posted its earnings results on Wednesday, August 14th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.03). The business had revenue of $2.26 million for the quarter, compared to the consensus estimate of $4.91 million. On average, analysts predict that Invivyd, Inc. will post -0.6 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Invivyd in a research note on Tuesday, September 3rd.

Invivyd Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.